通过纳入代谢影像生物标志物优化肝细胞癌患者的预后评估
回顾性分析56例肝细胞癌患者初始治疗前FDG PET/CT,测定SUVmax、TLG、MTV和TNR。确定SUVmax≥11.7、TLG≥1,341、MTV≥230 mL、TNR≥4.8为最佳截断值。多因素分析显示SUVmax≥11.7和TNR≥4.8在CLIP和BCLC系统中均为独立预后不良因素,TLG在BCLC系统中亦为独立因素。
要点
- 初始治疗前FDG PET/CT的SUVmax≥11.7和TNR≥4.8是肝细胞癌独立预后不良因素。
- TLG在BCLC分期系统中亦为独立预后因素。
- FDG PET/CT代谢参数可增加标准临床指标的预后价值。
核心结论
- 肝细胞癌患者初始治疗前FDG PET/CT可增加标准临床指标的预后价值。
- 应考虑将FDG PET/CT衍生的影像生物标志物纳入肝细胞癌分期系统。
研究设计与样本
- 回顾性分析2013年5月至2014年5月期间初始治疗前接受FDG PET/CT的肝细胞癌患者记录,共纳入56例。
- 测量四项PET/CT参数:SUVmax、TLG、MTV和TNR,确定总生存期(OS)的最佳截断值,并进行多因素分析评估其能否增加CLIP评分系统和BCLC分期系统的预后价值。
主要发现
- 单因素分析显示,PET/CT参数SUVmax、TLG以及肿瘤大小、总胆红素水平、碱性磷酸酶水平与OS的关联均为显著预测因素。
- 确定的截断值为SUVmax≥11.7、TLG≥1,341、MTV≥230 mL、TNR≥4.8。
- 多因素分析显示,SUVmax≥11.7和TNR≥4.8在CLIP评分系统和BCLC分期系统中均为预测不良预后的独立因素。
- TLG在BCLC分期系统中亦为预测不良预后的独立因素。
关键数值与推荐
- SUVmax最佳截断值为≥11.7。
- TLG最佳截断值为≥1,341。
- MTV最佳截断值为≥230 mL。
- TNR最佳截断值为≥4.8。
临床怎么用
- 原文结论认为肝细胞癌患者初始治疗前FDG PET/CT可增加标准临床指标的预后价值。
- 原文结论认为应考虑将FDG PET/CT衍生的影像生物标志物纳入肝细胞癌分期系统。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: 18F-fluorodeoxyglucose positron emission tomopraphy/computed tomography (FDGPET/CT) has been proven to be useful for imaging many types of cancer; however, its role is not well defined in hepatocellular carcinoma (HCC). We assessed the prognostic value of metabolic imaging biomarkers as established by baseline pretreatment FDG PET/CT in patients with HCC. METHODS: We retrospectively analyzed the records of patients with HCC who underwent FDG PET/CT before initial treatment from May 2013 through May 2014. Four PET/CT parameters were measured: maximum standardized uptake value (SUVmax), total lesion glycolysis (TLG), metabolic tumor volume (MTV), and tumor-to-normal-liver SUV ratio (TNR). Optimal cut-off values for the PET/CT parameters to stratify patients in terms of overall survival (OS) were determined. Multivariate analysis was performed to determine whether the PET/CT parameters could add to the prognostic value of the Cancer of the Liver Italian Program (CLIP) scoring system and the Barcelona-Clinic Liver Cancer (BCLC) staging system. RESULTS: The analysis included 56 patients. Univariate analysis of the association between OS and continuous variables, including the PET/CT parameters SUVmax, TLG, tumor size, total bilirubin level, and alkaline phosphatase level were significant predictors of OS. SUVmax ≥ 11.7, TLG ≥ 1,341, MTV ≥ 230 mL, and TNR ≥ 4.8 were identified as cut-off values. Multivariate analysis revealed that SUVmax ≥ 11.7 and TNR ≥ 4.8 were independent factors predicting a poor prognosis in both the CLIP scoring system and the BCLC staging system, as was TLG in the BCLC staging system. CONCLUSION: Pretreatment FDG PET/CT in patients with HCC can add to the prognostic value of standard clinical measures. Incorporation of imaging biomarkers derived from FDG PET/CT into HCC staging systems should be considered.
引用
- Takeuchi S, Rohren EM, Abdel-Wahab R, et al. Refining prognosis in patients with hepatocellular carcinoma through incorporation of metabolic imaging biomarkers. Eur J Nucl Med Mol Imaging. 2016. PMID: 27942837. doi:10.1007/s00259-016-3583-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。